Sanofi sharp­ens fo­cus on bis­pecifics, and Chi­na, with Al­pham­ab deal

It’s not the splashy ac­qui­si­tion Sanofi was ex­pect­ed to make af­ter pock­et­ing more than $11 bil­lion fol­low­ing the sale of a big chunk of part­ner Re­gen­eron’s stock, but it’s a start. On Tues­day, the com­pa­ny signed a pact with Chi­na’s Al­pham­ab On­col­o­gy to col­lab­o­rate on a bis­pe­cif­ic an­ti­body fo­cused on treat­ing breast can­cer.

The deal rep­re­sents Sanofi’s am­bi­tions in Chi­na, where sky­rock­et­ing rates of can­cer have sparked the cre­ation of biotech firms that have lured mil­lions in ven­ture fund­ing and pub­lic list­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER